News and Stories About immunotherapy
Persistence, Precision Medicine Pay off for Pancreatic Cancer Patient
When doctors told David Watson of Santa Monica, Calif., that he had type 2 diabetes in November 2016, he couldn’t […]
READ MORE
Meet Our 2018 Research Grantees: Translational Awards
This year, the Pancreatic Cancer Action Network (PanCAN) awarded nine prestigious research grants to scientists and clinicians in the United […]
READ MORE
New Research Suggests Age May Benefit Response to Immunotherapy
Cancer immunotherapy involves efforts to harness the patient’s own immune system to recognize and attack tumor cells. To date, the […]
READ MORE
Grantee Discusses Immunotherapy in Smithsonian Magazine
Pancreatic Cancer Action Network (PanCAN) grantee Dung Le, MD, provided commentary in the April 2018 issue of Smithsonian Magazine. The […]
READ MORE
Grantee’s Study Suggests Bacteria Can Influence Tumor Growth and Immune Response
Scientists have known for quite some time that pancreatic tumors are surrounded by an especially dense and complex “stroma,” a […]
READ MORE
2017 Year in Review: Top 10 News Stories
Editor’s note: This article is another installment in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE
Research Team’s Work Provides Clues that Explain Long-term Survival
A multi-institutional research team, including Vinod Balachandran, MD, and Steven Leach, MD, set out to ask an important question: “What […]
READ MORE
Discovery Channel Clinical Trials Series: Episode 2 – “Treatment”
The second episode of the three-part Discovery documentary on clinical trials, First in Human, follows the gripping story of three […]
READ MORE
New Findings Explain How Immune Cells Support Pancreatic Tumors
A Pancreatic Cancer Action Network Career Development Award in 2014 allowed David DeNardo, PhD, to ask and answer important questions […]
READ MORE
The Road to Effective Immunotherapy for Pancreatic Cancer Patients
Last week, we shared the exciting news that an immunotherapy agent, Keytruda, was the first drug approved by the FDA […]
READ MORE
Unprecedented Drug Approval Can Benefit Pancreatic Cancer Patients
For the first time, the U.S. Food and Drug Administration (FDA) has approved a cancer drug based only on molecular […]
READ MORE
Studying How a New Immunotherapy Works in Each Patient
Thanks to the generosity of donors, we awarded our largest-ever grant of $2 million in 2016 to accelerate a large-scale […]
READ MORE
A New Strategy to Allow Immune Attack of Pancreatic Tumors
The more researchers analyze the interaction between pancreatic cancer cells and the patient’s immune system, the more complex the relationship […]
READ MORE
Your Advocacy in Action: New Federal Research Funding to Explore Pancreatic Cancer Immunotherapy
Together, we have been relentless in fighting for increased funding for pancreatic cancer research and today, we are proud to […]
READ MORE
Grantee’s Preclinical Immunotherapy Data Shows Promise
Pancreatic cancer recently moved from the fourth to the third leading cause of cancer-related death in the United States, and […]
READ MORE
Grantee’s Early-Phase Immunotherapy Clinical Trial Shows Encouraging Results
Preliminary results from an early-phase immunotherapy clinical trial suggest that an innovative treatment could be effective for patients with locally-advanced or borderline-resectable pancreatic cancer.
